Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 4, 2012, Pages 494-502

  Siccardi, M ^a   Almond, L ^b   Schipani, A ^a   Csajka, C ^c   Marzolini, C ^d   Wyen, C ^e   Brockmeyer, N H ^f   Boffito, M ^g   Owen, A ^a   Back, D ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CERTARA UK LIMITED   (United Kingdom)

^c Hôpital Beaumont 06 634   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITY OF COLOGNE   (Germany)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; COMPARTMENT MODEL; DOSE RESPONSE; DRUG DOSE REDUCTION; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NEUROTOXICITY; POPULATION MODEL; PRIORITY JOURNAL; VIRUS INHIBITION;

ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; CACO-2 CELLS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, CHEMICAL; YOUNG ADULT;

EID: 84866624154     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.61     Document Type: Article

References (50)

1. csajka, C. et al. Population pharmacokinetics and efects of efavirenz in patients with human immunodefciency virus infection. Clin. Pharmacol. Ther. 73, 20-30 (2003).
2. Arab-Alameddine, M. et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin. Pharmacol. Ther. 85, 485-494 (2009).
3. Cabrera Figueroa, S., Iglesias Gómez, A., Sánchez Martín, A., de la Paz Valverde Merino, M., Domínguez-Gil Hurlé, A. & cordero Sánchez, M. Long-term efcacy and safety of efavirenz dose reduction to 200 mg once daily in a caucasian patient with HIV. Clin. Drug Investig. 30, 405-411 (2010).
4. Gatanaga, H. et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6*6 and*26. Clin. Infect. Dis. 45, 1230-1237 (2007).
5. van Luin, M. et al. Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations. J. Acquir. Immune Defc. Syndr. 52, 240-245 (2009).
6. Fayet Mello, A. et al. Successful efavirenz dose reduction guided by therapeutic drug monitoring. Antivir. Ther. (Lond.) 16, 189-197 (2011).
7. Marzolini, C., Telenti, A., Decosterd, L.A., Greub, G., Biollaz, J. & Buclin, t. Efavirenz plasma levels can predict treatment failure and central nervous system side efects in HIV-1-infected patients. AIDS 15, 71-75 (2001).
8. Ståhle, L., Moberg, L., Svensson, J.O. & Sönnerborg, A. Efavirenz plasma concentrations in HIV-infected patients: inter-and intraindividual variability and clinical efects. Ther. Drug Monit. 26, 267-270 (2004).
9. Leth, F.V. et al. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efcacy. AIDS Res. Hum. Retroviruses 22, 232-239 (2006).
10. Josephson, F. et al. the relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORtHIV trial of treatment-naïve HIV-1 infected patients. Eur. J. Clin. Pharmacol. 66, 349-357 (2010).
11. Johnson, D.H.et al. Pharmacogenetics, pharmacokinetics, and pharmacodynamics (PG/PK/PD) of central nervous system efects with single dose efavirenz. 12th International Workshop on clinical Pharmacology of HIV therapy. Miami, FL, 13-15 April 2011.
12. Núñez, M., González de Requena, D., Gallego, L., Jiménez-Nácher, I., González-Lahoz, J. & Soriano, V. Higher efavirenz plasma levels correlate with development of insomnia. J. Acquir. Immune Defc. Syndr. 28, 399-400 (2001).
13. Gutiérrez, F. et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin. Infect. Dis. 41, 1648-1653 (2005).
14. Cliford, D.B. et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann. Intern. Med. 143, 714-721 (2005).
15. Gallego, L. et al. Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz. Clin. Infect. Dis. 38, 430-432 (2004).
16. Nanzigu, S. et al. Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans. HIV Med. 13, 193-201 (2012).
17. Wintergerst, U. et al. Antiviral efcacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. J. Antimicrob. Chemother. 61, 1336-1339 (2008).
18. Sánchez, A. et al. Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in caucasian HIV-infected patients. Antimicrob. Agents Chemother. 55, 5314-5324 (2011).
19. Cohen, C.J., Colson, A.E., Sheble-Hall, A.G., McLaughlin, K.A. & Morse, G.D. Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-of (FOtO) study. HIV Clin. Trials 8, 19-23 (2007).
20. Rostami-Hodjegan, A. & tucker, G.t. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 6, 140-148 (2007).
21. Darwich, A.S., Neuhof, S., Jamei, M. & Rostami-Hodjegan, A. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Curr. Drug Metab. 11, 716-729 (2010).
22. Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G. & Rostami-Hodjegan, A. the Simcyp population-based ADME simulator. Expert Opin. Drug Metab. Toxicol. 5, 211-223 (2009).
23. Aarons, L. Population approaches/sparse data analysis for human variability in kinetics and dynamics. Environ. Toxicol. Pharmacol. 2, 197-199 (1996).
24. Sheiner, L.B. & Beal, S.L. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J. Pharmacokinet. Biopharm. 8, 553-571 (1980).
25. Takano, R. et al. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm. Res. 23, 1144-1156 (2006).
26. Ward, B.A., Gorski, J.C., Jones, D.R., Hall, S.D., Flockhart, D.A. & Desta, Z. the cytochrome P450 2B6 (cYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of cYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306, 287-300 (2003).
27. Ogburn, E.T., Jones, D.R., Masters, A.R., Xu, C., Guo, Y. & Desta, Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identifcation of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab. Dispos. 38, 1218-1229 (2010).
28. Bélanger, A.S., Harvey, M., Zimmerman, P.A., Mehlotra, R.K. & Guillemette, C. Glucuronidation of the antiretroviral drug efavirenz by UGt2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab. Dispos. 37, 1793-1796 (2009).
29. Faucette, S.R. et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defnes distinct classes of cYP2B6 and cYP3A4 inducers. J. Pharmacol. Exp. Ther. 320, 72-80 (2007).
30. Mouly, S. et al. Hepatic but not intestinal cYP3A4 displays dose-dependent induction by efavirenz in humans. Clin. Pharmacol. Ther. 72, 1-9 (2002).
31. Nyakutira, C. et al. High prevalence of the cYP2B6 516G-t(*6) variant and efect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur. J. Clin. Pharmacol. 64, 357-365 (2008).
32. Cabrera, S.E. et al. Infuence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodefciency virus patients. Antimicrob. Agents Chemother. 53, 2791-2798 (2009).
33. Lang, t. et al. Extensive genetic polymorphism in the human cYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11, 399-415 (2001).
34. Echeverría, P. et al. Similar antiviral efcacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study). Antiviral Res. 85, 403-408 (2010).
35. Torti, C. et al. Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAARt regimens in antiretroviral-naive HIV-positive patients: results from the Italian MAStER cohort. J. Antimicrob. Chemother. 56, 190-195 (2005).
36. Wyen, C. et al. cytochrome P450 2B6 (cYP2B6) and constitutive androstane receptor (cAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J. Antimicrob. Chemother. 66, 2092-2098 (2011).
37. Pérez-Molina, J.A. Safety and tolerance of efavirenz in diferent antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin. Trials 3, 279-286 (2002).
38. Hawkins, t. et al. comparison of neuropsychiatric side efects in an observational cohort of efavirenz-and protease inhibitor-treated patients. HIV Clin. Trials 6, 187-196 (2005).
39. Weiss, J., Herzog, M., König, S., Storch, C.H., Ketabi-Kiyanvash, N. & Haefeli, W.E. Induction of multiple drug transporters by efavirenz. J. Pharmacol. Sci. 109, 242-250 (2009).
40. Hubatsch, I., Ragnarsson, E.G. & Artursson, P. Determination of drug permeability and prediction of drug absorption in caco-2 monolayers. Nat. Protoc. 2, 2111-2119 (2007).
41. Moss, D.M. et al. Raltegravir is a substrate for SLc22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob. Agents Chemother. 55, 879-887 (2011).
42. Sun, D. et al. comparison of human duodenum and caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res. 19, 1400-1416 (2002).
43. Yu, L.X. & Amidon, G.L. Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur. J. Pharm. Biopharm. 45, 199-203 (1998).
44. Poulin, P. & theil, F.P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 91, 129-156 (2002).
45. Crewe, H.K., Barter, Z.E., Yeo, K.R. & Rostami-Hodjegan, A. Are there diferences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2c9? A systematic investigation into inter-system extrapolation factors. Biopharm. Drug Dispos. 32, 303-318 (2011).
46. Proctor, N.J., Tucker, G.t. & Rostami-Hodjegan, A. Predicting drug clearance from recombinantly expressed cYPs: intersystem extrapolation factors. Xenobiotica. 34, 151-178 (2004).
47. Knebel, B.T., Gibiansky, L., Hane, J.t. & M.R., G. MQual: a tool to automate installation and facilitate qualifcation of NONMEM. 14th Population Approach Group Europe. Pamplona, Spain, 16-17 June 2005.
48. Bristol-Myers Squibb. Approval documentation for Sustiva ™ (Efavirenz) NDA no 020972, 2009.
49. DRUGBANK. citalopram, accession number DB00215 (APRD00147) http://www.drugbank.ca/drugs/DB00215.
50. Rabel, S.R., Maurin, M.B., Rowe, S.M. & Hussain, M. Determination of the pKa and pH-solubility behavior of an ionizable cyclic carbamate, (S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifuoromethyl)-2H-3, 1-benzoxazin-2-one (DMP 266). Pharm. Dev. Technol. 1, 91-95 (1996).